Reversing LRP5-Dependent Osteoporosis and SOST Deficiency-Induced Sclerosing Bone Disorders by Altering WNT Signaling Activity

被引:63
作者
Chang, Ming-Kang [1 ]
Kramer, Ina [1 ]
Keller, Hansjoerg [1 ]
Gooi, Jonathan H. [1 ]
Collett, Corinne [2 ]
Jenkins, David [3 ]
Ettenberg, Seth A. [3 ]
Cong, Feng [3 ]
Halleux, Christine [1 ]
Kneissel, Michaela [1 ]
机构
[1] Novartis Inst BioMed Res, Musculoskeletal Dis Area, CH-4002 Basel, Switzerland
[2] Hop Lariboisiere, AP HP, Serv Biochim, Natl Inst Hlth & Med Res,U942, F-75475 Paris, France
[3] Novartis Inst BioMed Res, Cambridge, MA USA
关键词
SOST; SCLEROSTIN; WNT; LRP5; 6; OSTEOPOROSIS-PSEUDOGLIOMA; OPPG; SCLEROSING BONE DISORDERS; GENETIC ANIMAL MODELS; LRP5; MUTATIONS; MASS; GENE; INHIBITION; DENSITY; MICE; DELETION; BINDING; LIGAND;
D O I
10.1002/jbmr.2059
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The bone formation inhibitor sclerostin encoded by SOST binds in vitro to low-density lipoprotein receptor-related protein (LRP) 5/6 Wnt co-receptors, thereby inhibiting Wnt/-catenin signaling, a central pathway of skeletal homeostasis. Lrp5/LRP5 deficiency results in osteoporosis-pseudoglioma (OPPG), whereas Sost/SOST deficiency induces lifelong bone gain in mice and humans. Here, we analyzed the bone phenotype of mice lacking Sost (Sost(-/-)), Lrp5 (Lrp5(-/-)), or both (Sost(-/-);Lrp5(-/-)) to elucidate the mechanism of action of Sost in vivo. Sost deficiency-induced bone gain was significantly blunted in Sost(-/-);Lrp5(-/-) mice. Yet the Lrp5 OPPG phenotype was fully rescued in Sost(-/-);Lrp5(-/-) mice and most bone parameters were elevated relative to wild-type. To test whether the remaining bone increases in Sost(-/-);Lrp5(-/-) animals depend on Lrp6, we treated wild-type, Sost(-/-), and Sost(-/-);Lrp5(-/-) mice with distinct Lrp6 function blocking antibodies. Selective blockage of Wnt1 class-mediated Lrp6 signaling reduced cancellous bone mass and density in wild-type mice. Surprisingly, it reversed the abnormal bone gain in Sost(-/-) and Sost(-/-);Lrp5(-/-) mice to wild-type levels irrespective of enhancement or blockage of Wnt3a class-mediated Lrp6 activity. Thus, whereas Sost deficiency-induced bone anabolism partially requires Lrp5, it fully depends on Wnt1 class-induced Lrp6 activity. These findings indicate: first, that OPPG syndrome patients suffering from LRP5 loss-of-function should benefit from principles antagonizing SOST/sclerostin action; and second, that therapeutic WNT signaling inhibitors may stop the debilitating bone overgrowth in sclerosing disorders related to SOST deficiency, such as sclerosteosis, van Buchem disease, and autosomal dominant craniodiaphyseal dysplasia, which are rare disorders without viable treatment options. (c) 2014 American Society for Bone and Mineral Research.
引用
收藏
页码:29 / 42
页数:14
相关论文
共 65 条
  • [1] Structural Basis of Wnt Signaling Inhibition by Dickkopf Binding to LRP5/6
    Ahn, Victoria E.
    Chu, Matthew Ling-Hon
    Choi, Hee-Jung
    Tran, Denise
    Abo, Arie
    Weis, William I.
    [J]. DEVELOPMENTAL CELL, 2011, 21 (05) : 862 - 873
  • [2] Reduced affinity to and inhibition by DKK1 form a common mechanism by which high bone mass-associated missense mutations in LRP5 affect canonical Wnt signaling
    Ai, M
    Holmen, SL
    Van Hul, W
    Williams, BO
    Warman, ML
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 2005, 25 (12) : 4946 - 4955
  • [3] Teriparatide Increases Bone Mineral Density in a Man With Osteoporosis Pseudoglioma
    Arantes, Henrique Pierotti
    Barros, Elizabete Ribeiro
    Kunii, Ilda
    Bilezikian, John P.
    Lazaretti-Castro, Marise
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2011, 26 (12) : 2823 - 2826
  • [4] Ayturk U M., 2013, Journal of Bone and Mineral Research
  • [5] High bone mass in mice expressing a mutant LRP5 gene
    Babij, P
    Zhao, WG
    Small, C
    Kharode, Y
    Yaworsky, PJ
    Bouxsein, ML
    Reddy, PS
    Bodine, PVN
    Robinson, JA
    Bhat, B
    Marzolf, J
    Moran, RA
    Bex, F
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2003, 18 (06) : 960 - 974
  • [6] Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease
    Balemans, W
    Patel, N
    Ebeling, M
    Van Hul, E
    Wuyts, W
    Lacza, C
    Dioszegi, M
    Dikkers, FG
    Hildering, P
    Willems, PJ
    Verheij, JBGM
    Lindpaintner, K
    Vickery, B
    Foernzler, D
    Van Hul, W
    [J]. JOURNAL OF MEDICAL GENETICS, 2002, 39 (02) : 91 - 97
  • [7] Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)
    Balemans, W
    Ebeling, M
    Patel, N
    Van Hul, E
    Olson, P
    Dioszegi, M
    Lacza, C
    Wuyts, W
    Van den Ende, J
    Willems, P
    Paes-Alves, AF
    Hill, S
    Bueno, M
    Ramos, FJ
    Tacconi, P
    Dikkers, FG
    Stratakis, C
    Lindpaintner, K
    Vickery, B
    Foernzler, D
    Van Hul, W
    [J]. HUMAN MOLECULAR GENETICS, 2001, 10 (05) : 537 - 543
  • [8] The binding between sclerostin and LRP5 is altered by DKK1 and by high-bone mass LRP5 mutations
    Balemans, Wendy
    Piters, Elke
    Cleiren, Erna
    Ai, Minrong
    Van Wesenbeeck, Liesbeth
    Warman, Matthew L.
    Van Hul, Wim
    [J]. CALCIFIED TISSUE INTERNATIONAL, 2008, 82 (06) : 445 - 453
  • [9] WNT signaling in bone homeostasis and disease: from human mutations to treatments
    Baron, Roland
    Kneissel, Michaela
    [J]. NATURE MEDICINE, 2013, 19 (02) : 179 - 192
  • [10] Regulation of osteoblastogenesis and bone mass by Wnt10b
    Bennett, CN
    Longo, KA
    Wright, WS
    Suva, LJ
    Lane, TF
    Hankenson, KD
    MacDougald, OA
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (09) : 3324 - 3329